Gi Innovation, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jul 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 2, 2027The maintenance fee for Pharmaceutical Composition for Cancer Treatment Comprising Fusion Protein Including IL-2 Protein and CD80 Protein and Anticancer Drug (US 11,857,601) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,410,233 | Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,492,384 | Fusion Protein Comprising IL-2 Protein and CD80 Protein, and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,857,601 | Pharmaceutical Composition for Cancer Treatment Comprising Fusion Protein Including IL-2 Protein and CD80 Protein and Anticancer Drug In force · High confidence | In force | High confidence | |
| US 12,286,464 | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,639,383 | Pharmaceutical Composition for Treatment of Cancer, Comprising an Immune Checkpoint Inhibitor Antibody and a Fusion Protein Comprising an IL-2 Mutant and a CD80 Extracellular Domain In force · High confidence | In force | High confidence | |
| US 12,291,555 | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,128,076 | Composition Comprising Probiotics and Polypeptide Having Binding Affinity for Ige and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,409,203 | Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same In force · From the USPTO record | In force | From the USPTO record | |
| US 12,478,675 | Pharmaceutical composition for enhancing radiotherapy comprising fusion protein containing IL-2 protein and CD80 protein In force · From the USPTO record | In force | From the USPTO record | |
| US 12,692,307 | Pharmaceutical Composition for Treatment of Cancer, Comprising an Immune Checkpoint Inhibitor Antibody and a Fusion Protein Comprising an IL-2 Mutant and a CD80 Extracellular Domain In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending